EPO Patents = 1

Forward Citations = 0

Loading Chart...

5 inventors (with patents filed for the assignee):

Steven A Rich (4 out of 11 patents)

Bingidimi Itute Mobele (1 out of 9 patents)

Satish Puppali (1 out of 15 patents)

4. Emerich Eisenreich (1 out of 5 patents)

5. Xuejun Karl Liu (1 out of 5 patents)

4 patents: Sort by Forward Citations

1. 12109202 - Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders (2024-10-08),

2. 11419850 - Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases (2022-08-23),

3. 10519109 - Glycopyrronium fatty acid salts and methods of making same (2019-12-31),

4. 10376493 - Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases (2019-08-13),

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

4 Patents

#6 in Canandaigua, NY

#3,682 in New York

#60,671 in US

Canandaigua, NY, United States of America

Qaam Pharmaceuticals, LLC

Forward Citations = 0

5 inventors:

Steven A Rich (4 out of 11 patents)

Bingidimi Itute Mobele (1 out of 9 patents)

Satish Puppali (1 out of 15 patents)

4. Emerich Eisenreich (1 out of 5 patents)

5. Xuejun Karl Liu (1 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Qaam Pharmaceuticals, LLC. Retrieved from https://idiyas.com/company/qaam-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]